Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial ...

CLEVELAND — It's common knowledge that our personal devices can collect data about the things we watch and listen to, and that includes your smart TV too. We came across this blog post about ...

If you prefer the excitement of poker tournaments over cash games, but don’t have the time for them, check out ACR Poker’s latest offering. If you’re looking for quick action, Lightning PKOs ...

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T therapies ...